Piramal Pharma Ltd (PPLPHARMA) Q1 FY27 Results Analysis: EBITDA Surges 72%, Margin Expands 400 bps

Piramal Pharma Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 2,269.92 Cr (+17.40% YoY) and PAT growth of +15.10% YoY. Here's a quick read of what worked, what to watch, and what management said.

Key Investment Insights

Key Positives

• Revenue grew 17.4% YoY to Rs.2,269.92 Cr, the first positive YoY growth quarter in four quarters
• EBITDA grew 72.4% YoY to Rs.284.61 Cr, with margin expanding 400 bps to 12.54%
• PAT loss narrowed 15.1% YoY to Rs.(69.39) Cr; normalized PAT improved 31.9% YoY
• Subsidiary drag reduced from Rs.(194.84) Cr to Rs.(182.87) Cr, indicating loss reduction
• Kenalog acquisition contributed first full quarter of revenue (annualized guidance US$30-40 Mn)

Risk Factors

• Consolidated PAT loss of Rs.(69.39) Cr persists, with path to full-year positive PAT requiring sustained margin expansion and subsidiary loss reduction
• Tax charge of Rs.61.93 Cr on a negative PBT due to tax asymmetry between profitable standalone and loss-making subsidiaries
• Employee benefits expense increased 15.3% QoQ to Rs.675.63 Cr, requiring explanation on the earnings call
• Net debt/EBITDA elevated at 3.6x as of Q4 FY26, with deleveraging to 1x targeted by FY30